This significant milestone comes ahead of schedule, halfway to enrolling the total goal of 500 patients. The global study is still open for patient enrollment in sites across
'The speed at which patients are being enrolled into the trial is demonstrative of the tremendous need there is for effective treatments for metastatic pancreatic cancer and the hope people have in cancer metabolism,' said
The principal investigator on Rafael's Phase 3 clinical trial for patients with pancreatic cancer is
'It is incredible to announce that we've reached 250 patients in this pivotal clinical trial for one of the deadliest cancers in the world,' said
About CPI-613 (devimistat)
CPI-613 (devimistat) is a first-in-class clinical lead compound of Rafael, which targets enzymes that are involved in cancer cell energy metabolism and are located in the mitochondria of cancer cells. Devimistat is designed to target the mitochondrial tricarboxylic acid (TCA) cycle, a process essential to tumor cell multiplication and survival, selectively in cancer cells. Devimistat substantially increases the sensitivity of cancer cells to a diverse range of chemotherapeutic agents. This synergy allows for potential combinations of devimistat with lower doses of these generally toxic drugs to be more effective with lower patient's side effects. Combination with devimistat represent a diverse range of opportunities to substantially improve patient's benefit in many different cancers. The
About
Safe Harbor Statement
This press release contains forward-looking statements. These statements relate to future events or the company's future financial performance. In some cases, you can identify forward-looking statements by terminology such as 'may', 'will', 'should', 'expect', 'plan', 'anticipate', 'believe', 'estimate', 'predict', 'potential' or 'continue', the negative of such terms, or other comparable terminology. These statements are only predictions. Actual events or results may differ materially from those in the forward-looking statements as a result of various important factors. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the company, or any other person, that such forward-looking statements will be achieved. The business and operations of the company are subject to substantial risks which increase the uncertainty inherent in forward-looking statements. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements.
Contact:
Tel: (201) 465-8019
Email: rafael@antennagroup.com
(C) 2020 Electronic News Publishing, source